NASDAQ · OKYO
OKYO Pharma Limited
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
Loading market information…
OTC · RTNXF · USD
Stock price, earnings
Quote as of Feb 7, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 87.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Renalytix Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Renalytix Plc specializes in developing artificial intelligence-driven in vitro diagnostic solutions for kidney diseases. Its flagship offering, KidneyIntelX, is a sophisticated diagnostic platform. This system leverages an AI-powered algorithm that integrates diverse data inputs, including validated blood-based biomarkers, an individual's inherited genetics, and personalized patient data extracted from electronic health records, to generate a unique risk score for each patient. These innovations serve several critical applications, such as diagnosing and forecasting the progression of kidney disease, guiding clinical patient management, aiding in patient selection for pharmaceutical trials, and discovering novel drug targets. The company has forged strategic alliances, including licensing agreements with prominent institutions. It collaborates with Mount Sinai Health System for the development and commercialization of AI-driven diagnostic tools for renal conditions. Another agreement is with Joslin Diabetes Center, Inc., focusing on developing and marketing products for kidney disease diagnosis and prediction using biomarkers. Additionally, a partnership with Kantaro Biosciences LLC is dedicated to creating and commercializing laboratory tests for detecting SARS-CoV-2 antibodies. Furthermore, Renalytix has formed a significant collaboration with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care model designed to bolster kidney health and mitigate the advancement of kidney disease and renal failure among at-risk populations. Incorporated in 2018, Renalytix Plc is headquartered in New York, New York. The company adopted its current name in June 2021, having previously operated as Renalytix AI plc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Sep 28, 2023 | -$0.06-1.82% vs estimate | $518.00K-37.08% vs estimate |
|---|
| Q3 2023 | Jun 9, 2023 | -$0.07-24.89% vs estimate | $724.00K-51.08% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
$1.04+$0.04 (+3.5%)
U.S. NeuroSurgical Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.65% below the high.
$3.75+$0.01 (+0.27%)
PharmChem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.78% below the high.
$0.39-$0.00 (-0.39%)
HS GovTech Solutions Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.22% below the high.
$0.00$0.00 (0.0%)
Yourgene Health Plc: Healthcare · Medical - Diagnostics & Research.
$0.16-$0.03 (-15.36%)
TPCO Holding Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.81% below the high.
€2.94-€0.11 (-3.61%)
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 43.24% below the high.
